# Anticancer Bioscience

Source: https://onco.cc/companies/anticancer-bioscience/  
OnCo record `anticancer-bioscience` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Anticancer Bioscience develops tablet medicines meant to kill cancer cells that depend on the MYC gene, chosen with a test for MYC; its first drug has just entered an early trial.

## Summary

Chengdu Anticancer Bioscience, Ltd. states that it translates MYC synthetic lethality into biomarker-driven cancer therapies, and lists locations in Chengdu, St Andrews (UK), San Francisco, Sydney and Hyderabad. JMBI-001 tablets are in a phase 1/2 study in adults with MYC-positive advanced cancers, including solid tumours and non-Hodgkin lymphoma (NCT07864701). Its first registered cancer trial, NCT07864701, was posted on ClinicalTrials.gov in October 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Chengdu Anticancer Bioscience, Ltd.
- HQ: Chengdu
- Type: biotech
- Website: https://www.anticancerbio.com/

## Notes

- The company website was a holding page on 29 October 2026 ('Our website will be live soon'), stating only the MYC synthetic lethality focus and its locations. Founding year, financing and the mechanism of JMBI-001 beyond the registry title were not available. Treat this record as thin.

## Sources

- Official website: https://www.anticancerbio.com/
- ClinicalTrials.gov: phase 1/2 trial of JMBI-001 (NCT07864701): https://clinicaltrials.gov/study/NCT07864701

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Synthetic lethality approaches](https://onco.cc/technologies/synthetic-lethality-approaches/)
- targets: [MYC](https://onco.cc/targets/myc-gene/)

---
JSON: https://onco.cc/api/v1/entities/anticancer-bioscience.json